Flufenamic acid suppresses epileptiform activity in hippocampus by reducing excitatory synaptic transmission and neuronal excitability

被引:17
作者
Fernandez, Miriam [1 ]
Lao-Peregrin, Cristina [1 ]
Martin, Eduardo D. [1 ]
机构
[1] Univ Castilla La Mancha, Reg Ctr Biomed Res CRIB, Lab Neurophysiol & Synapt Plast, Albacete 02006, Spain
关键词
Synaptic transmission; Glutamate release; NMDA; Non-NMDA; Fenamates; NSAIDs; ANTI-INFLAMMATORY DRUGS; CA1 PYRAMIDAL NEURONS; ANTIEPILEPTIC DRUGS; PAIRED-PULSE; IN-VITRO; RAT; EPILEPSY; EPILEPTOGENESIS; INHIBITION; CURRENTS;
D O I
10.1111/j.1528-1167.2009.02279.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
P>Purpose: In this study, we explore the antiepileptic effects of flufenamic acid (FFA) in order to identify the cellular mechanisms that underlie the potential anticonvulsant properties of this nonsteroidal antiinflammatory compound. Methods: The mechanisms of FFA action were analyzed using an in vitro model in which epileptiform activity was induced in hippocampal slices by perfusion with 100 mu m 4-aminopyridine (4-AP) added to a modified Mg2+-free solution. The activity of CA1 pyramidal neurons as well as the synaptic connection between CA3 and CA1 was monitored using extracellular and patch-clamp recordings. Results: Epileptiform activity was suppressed in hippocampal neurons by FFA at concentrations between 50 and 200 mu m. Glutamatergic excitatory synaptic transmission was diminished by FFA without modifying recurrent gamma-aminobutyric acid (GABA)ergic synaptic inhibition. Several lines of evidence indicated that FFA did not decrease neurotransmitter release probability, implicating a postsynaptic mechanism of action. FFA also potently reduced neuronal excitability, but did not alter the amplitude, duration, or undershoot of action potentials. Conclusions: Our results suggest that FFA exerts an anticonvulsive effect on hippocampal pyramidal neurons by simultaneously decreasing glutamatergic excitatory synaptic activity and reducing neuronal excitability. Therefore, our study provides experimental evidence that FFA may represent an effective pharmacologic agent in the treatment of epilepsy in the mammalian central nervous system.
引用
收藏
页码:384 / 390
页数:7
相关论文
共 40 条
  • [11] EXPRESSION AND SELECTIVE-INHIBITION OF THE CONSTITUTIVE AND INDUCIBLE FORMS OF HUMAN CYCLOOXYGENASE
    GIERSE, JK
    HAUSER, SD
    CREELY, DP
    KOBOLDT, C
    RANGWALA, SH
    ISAKSON, PC
    SEIBERT, K
    [J]. BIOCHEMICAL JOURNAL, 1995, 305 : 479 - 484
  • [12] First seizure definitions and worldwide incidence and mortality
    Hauser, W. Allen
    Beghi, Ettore
    [J]. EPILEPSIA, 2008, 49 : 8 - 12
  • [13] ANALYSIS OF EXCITATORY SYNAPTIC ACTION IN PYRAMIDAL CELLS USING WHOLE-CELL RECORDING FROM RAT HIPPOCAMPAL SLICES
    HESTRIN, S
    NICOLL, RA
    PERKEL, DJ
    SAH, P
    [J]. JOURNAL OF PHYSIOLOGY-LONDON, 1990, 422 : 203 - 225
  • [14] DIFFERENTIAL-EFFECTS OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS ON SEIZURES PRODUCED BY PILOCARPINE IN RATS
    IKONOMIDOUTURSKI, C
    CAVALHEIRO, EA
    TURSKI, L
    BORTOLOTTO, ZA
    KLEINROK, Z
    CALDERAZZO, LS
    TURSKI, WA
    [J]. BRAIN RESEARCH, 1988, 462 (02) : 275 - 285
  • [15] Jallon P, 1997, EPILEPSIA, V38, P1143, DOI 10.1111/j.1528-1157.1997.tb01205.x
  • [16] SYNAPTIC AND INTRINSIC RESPONSES OF MEDIAL ENTORHINAL CORTICAL-CELLS IN NORMAL AND MAGNESIUM-FREE MEDIUM INVITRO
    JONES, RSG
    HEINEMANN, U
    [J]. JOURNAL OF NEUROPHYSIOLOGY, 1988, 59 (05) : 1476 - 1496
  • [17] Ca2+-activated Cl- channel currents in rat ventral prostate epithelial cells
    Kim, SJ
    Shin, SY
    Lee, JE
    Kim, JH
    Uhm, DY
    [J]. PROSTATE, 2003, 55 (02) : 118 - 127
  • [18] Diclofenac inhibition of sodium currents in rat dorsal root ganglion neurons
    Lee, HM
    Kim, HI
    Shin, YK
    Lee, CS
    Park, M
    Song, JH
    [J]. BRAIN RESEARCH, 2003, 992 (01) : 120 - 127
  • [19] Inhibition of hKv2.1, a major human neuronal voltage-gated K+ channel, by meclofenamic acid
    Lee, YT
    Wang, Q
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1999, 378 (03) : 349 - 356
  • [20] LERMA J, 1992, MOL PHARMACOL, V41, P217